SCHEMBL4016045

SCHEMBL4016045

CCCCCCNS(=O)(=O)c1ccc(CN(Cc2cccc(C(F)(F)F)c2)C(=O)C(=O)O)s1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
TRPV1 Q8NER1 1/20 0.40
SERPINE1 P05121 2/20 0.39
IDH2 P48735 1/20 0.38
PTGES O14684 2/20 0.38
EPHX1 P07099 2/20 0.37
UBE2M P61081 4/20 0.37
DCUN1D1 Q96GG9 4/20 0.37
NR3C1 P04150 1/20 0.37
LMNA P02545 2/20 0.37
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1854854 1.00 SMN1; SMN2 (0.42) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL4024326 0.90 MAPK1 (0.46) SMN1; SMN2TSHRSERPINE1PTGESNR3C1
SCHEMBL1853297 0.89 SMN1; SMN2 (0.45) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL1852104 0.88 KMT2A (0.50) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL1856431 0.87 SMN1; SMN2 (0.50) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL4022922 0.87 EPHX1 (0.39) SMN1; SMN2TSHRHTTTRPV1SERPINE1
SCHEMBL1853214 0.86 TSHR (0.43) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL1852522 0.85 TRPM8 (0.43) SMN1; SMN2MEN1KMT2ASERPINE1PTGES
SCHEMBL4016855 0.84 MEN1 (0.41) SMN1; SMN2MEN1TSHRHTTKMT2A
SCHEMBL1853216 0.84 SMN1; SMN2 (0.44) SMN1; SMN2MEN1TSHRHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 SMN1; SMN2 2147/4885MEN1 2947/4885TSHR 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.